SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model

Vaccine

Volumn 28, Issue 36, 2010, Pages 5794-5802

  Sharma, Rajesh K ^a   Srivastava, Abhishek K ^a   Yolcu, Esma S ^a   MacLeod, Kathryn J ^b   Schabowsky, Rich Henry ^a   Madireddi, Shravan ^a   Shirwan, Haval ^a  

^a University of Louisville School of Medicine   (United States)

^b ApoImmune Inc   (United States)

Author keywords

Adjuvant; Cervical cancer; Costimulation; Human papillomavirus; SA 4 1BBL; Vaccine

Indexed keywords

CANCER VACCINE; CD137 LIGAND; PROTEIN E7; STREPTAVIDIN; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EFFECTOR CELL; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MEMORY CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; OPTIMAL DRUG DOSE; PLEIOTROPY; PRIORITY JOURNAL; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; UTERINE CERVIX CANCER;

4-1BB LIGAND; AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLONING, MOLECULAR; FEMALE; HUMAN PAPILLOMAVIRUS 16; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; STREPTAVIDIN; UTERINE CERVICAL NEOPLASMS; VACCINES, SUBUNIT;

EID: 77955560503     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.073     Document Type: Article

References (40)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
2. Brandsma J.L., Abramson A.L. Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg 1989, 115:621-625.
3. Schmiedeskamp M.R., Kockler D.R. Human papillomavirus vaccines. Ann Pharmacother 2006, 40:1344-1352.
4. Monie A., Hung C.F., Wu T.C. Preventive and therapeutic HPV vaccines. Curr Opin Investig Drugs 2007, 8:1038-1050.
5. Chen L., Ashe S., Singhal M.C., Galloway D.A., Hellstrom I., Hellstrom K.E. Metastatic conversion of cells by expression of human papillomavirus type 16 E6 and E7 genes. Proc Natl Acad Sci USA 1993, 90:6523-6527.
6. Jochmus-Kudielka I., Schneider A., Braun R., Kimmig R., Koldovsky U., Schneweis K.E., et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989, 81:1698-1704.
7. Kim T.Y., Myoung H.J., Kim J.H., Moon I.S., Kim T.G., Ahn W.S., et al. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res 2002, 62:7234-7240.
8. Cui Z., Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother 2005, 54:1180-1190.
9. Huang Y., Obholzer N., Fayad R., Qiao L. Turning on/off tumor-specific CTL response during progressive tumor growth. J Immunol 2005, 175:3110-3116.
10. Elpek K.G., Lacelle C., Singh N.P., Yolcu E.S., Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol 2007, 178:6840-6848.
11. Finn O.J. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003, 3:630-641.
12. Lin K.Y., Lu D., Hung C.F., Peng S., Huang L., Jie C., et al. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 2007, 67:1832-1841.
13. Sharma R.K., Elpek K.G., Yolcu E.S., Schabowsky R.H., Zhao H., Bandura-Morgan L., et al. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res 2009, 69:4319-4326.
14. Bertram E.M., Lau P., Watts T.H. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J Immunol 2002, 168:3777-3785.
15. Waller E.C., McKinney N., Hicks R., Carmichael A.J., Sissons J.G., Wills M.R. Differential costimulation through CD137 (4-1BB) restores proliferation of human virus-specific " effector memory" (CD28(-) CD45RA(HI)) CD8(+) T cells. Blood 2007, 110:4360-4366.
16. Uno T., Takeda K., Kojima Y., Yoshizawa H., Akiba H., Mittler R.S., et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006, 12:693-698.
17. Rabu C., Quemener A., Jacques Y., Echasserieau K., Vusio P., Lang F. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem 2005, 280:41472-41481.
18. Elpek K.G., Yolcu E.S., Franke D.D., Lacelle C., Schabowsky R.H., Shirwan H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol 2007, 179:7295-7304.
19. Schabowsky R.H., Elpek K.G., Madireddi S., Sharma R.K., Yolcu E.S., Bandura-Morgan L., et al. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine 2009, 28:512-522.
20. Gomez-Gutierrez J.G., Elpek K.G., Montes dO-L., Shirwan H., Sam Z.H., McMasters K.M. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 2007, 56:997-1007.
21. Munger K., Basile J.R., Duensing S., Eichten A., Gonzalez S.L., Grace M., et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001, 20:7888-7898.
22. Saito T., Takayama T., Osaki T., Nagai S., Suzuki T., Sato M., et al. Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity. Cancer Sci 2008, 99:2028-2036.
23. Pulle G., Vidric M., Watts T.H. IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J Immunol 2006, 176:2739-2748.
24. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005, 23:23-68.
25. Quezada S.A., Peggs K.S., Simpson T.R., Shen Y., Littman D.R., Allison J.P. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008, 205:2125-2138.
26. Rubin J.T., Elwood L.J., Rosenberg S.A., Lotze M.T. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 1989, 49:7086-7092.
27. Melero I., Johnston J.V., Shufford W.W., Mittler R.S., Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998, 190:167-172.
28. Wilcox R.A., Flies D.B., Zhu G., Johnson A.J., Tamada K., Chapoval A.I., et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002, 109:651-659.
29. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
30. Indrova M., Bieblova J., Jandlova T., Vonka V., Pajtasz-Piasecka E., Reinis M. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours. Int J Oncol 2006, 28:253-259.
31. Georgopoulos N.T., Proffitt J.L., Blair G.E. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 2000, 19:4930-4935.
32. Cheng W.F., Hung C.F., Lee C.N., Su Y.N., Chang M.C., He L., et al. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways. Eur J Immunol 2004, 34:1892-1900.
33. Xu D., Gu P., Pan P.Y., Li Q., Sato A.I., Chen S.H. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer 2004, 109:499-506.
34. Lee S.W., Salek-Ardakani S., Mittler R.S., Croft M. Hypercostimulation through 4-1BB distorts homeostasis of immune cells. J Immunol 2009, 182:6753-6762.
35. Niu L., Strahotin S., Hewes B., Zhang B., Zhang Y., Archer D., et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2007, 178:4194-4213.
36. Greenhalgh D.A., Wang X.J., Rothnagel J.A., Eckhardt J.N., Quintanilla M.I., Barber J.L., et al. Transgenic mice expressing targeted HPV-18 E6 and E7 oncogenes in the epidermis develop verrucous lesions and spontaneous, rasHa-activated papillomas. Cell Growth Differ 1994, 5:667-675.
37. Yan J., Reichenbach D.K., Corbitt N., Hokey D.A., Ramanathan M.P., McKinney K.A., et al. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine 2009, 27:431-440.
38. Gunn G.R., Zubair A., Peters C., Pan Z.K., Wu T.C., Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001, 167:6471-6479.
39. Kumaraguru U., Banerjee K., Rouse B.T. In vivo rescue of defective memory CD8+ T cells by cognate helper T cells. J Leukoc Biol 2005, 78:879-887.
40. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300:337-339.